GO:0045295 gamma-catenin binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0045295 gamma-catenin binding is a molecular function defined as binding to the catenin complex gamma subunit, also known as plakoglobin.
• Gamma-catenin (plakoglobin) is a dual junctional protein found in both desmosomes and adherens junctions, where it links cadherins to the cytoskeleton.
• In cancer, gamma-catenin can compensate for beta-catenin loss and drive oncogenic signaling, particularly in hepatocellular carcinoma and pancreatic cancer.
• The gamma-catenin/CBP complex maintains survivin transcription in beta-catenin-deficient cancer cells, revealing a beta-catenin-independent survival mechanism.
• Disruption of beta-catenin/BCL9 protein-protein interactions represents a therapeutic strategy, though direct gamma-catenin binding partners remain under investigation.
• Cholinergic signaling impairs cardiomyocyte cohesion, highlighting the importance of gamma-catenin binding in cardiac tissue integrity.
Description
Gamma-catenin binding (GO:0045295) is a molecular function that describes the physical interaction with the gamma subunit of the catenin complex, commonly known as plakoglobin. This binding event is fundamental to cell-cell adhesion and signal transduction, as gamma-catenin is a key component of both desmosomes and adherens junctions. Unlike beta-catenin, which is primarily associated with adherens junctions and Wnt signaling, gamma-catenin is unique in its ability to participate in both junctional types, making it a critical node in tissue architecture and mechanotransduction. Researchers study gamma-catenin binding to understand how cells maintain structural integrity and how disruption of these interactions contributes to diseases such as cancer and cardiomyopathy. The functional importance of gamma-catenin binding is underscored by its role in hepatocellular carcinoma, where it can substitute for beta-catenin to promote tumorigenesis. In pancreatic cancer, FOXM1-JUP signaling drives oncogenic programs, further implicating gamma-catenin in disease progression. Additionally, the gamma-catenin/CBP complex sustains survivin transcription in beta-catenin-deficient cancer cells, providing a survival advantage. These findings position gamma-catenin binding as a promising target for therapeutic intervention and a subject of intense research interest.
gamma-catenin binding At A Glance
| GO ID | GO:0045295 |
|---|---|
| GO term | gamma-catenin binding |
| Ontology | molecular_function |
| Synonym | plakoglobin binding |
| Definition | Binding to catenin complex gamma subunit. |
| Major function | Mediates cell-cell adhesion and signal transduction by linking cadherins to the cytoskeleton. |
| Related proteins | Gamma-catenin (JUP), desmoglein, desmocollin, E-cadherin, alpha-catenin, beta-catenin. |
| Cellular context | Desmosomes and adherens junctions. |
| Disease relevance | Cancer (hepatocellular, pancreatic), cardiomyocyte cohesion defects. |
What Is GO:0045295?
According to the Gene Ontology, GO:0045295 gamma-catenin binding is defined as the binding to the catenin complex gamma subunit. In other words, it is the molecular function of physically interacting with gamma-catenin (plakoglobin), a protein that is part of the catenin complex. This binding can occur through various protein domains and is essential for assembling junctional complexes and transmitting signals.
Why Is gamma-catenin binding Important in Cell Biology?
Gamma-catenin binding is critically important because it governs the assembly and stability of desmosomes and adherens junctions, which are essential for tissue integrity and barrier function. Dysregulation of this binding is implicated in cancer progression, where gamma-catenin can act as an oncogene or compensate for beta-catenin loss. Moreover, gamma-catenin binding influences transcriptional programs through interactions with CBP, affecting cell survival and proliferation. In the heart, impaired gamma-catenin binding leads to cardiomyocyte cohesion defects, contributing to arrhythmogenic cardiomyopathy. Thus, understanding gamma-catenin binding provides insights into fundamental cell biology and offers potential therapeutic targets for cancer and cardiac diseases.
• Maintains tissue architecture by anchoring cadherins to the cytoskeleton in desmosomes and adherens junctions.
• Compensates for beta-catenin loss in cancer, promoting tumorigenesis in hepatocellular carcinoma.
• Drives pancreatic cancer progression through FOXM1-JUP signaling.
• Sustains survivin transcription via the gamma-catenin/CBP complex, supporting cancer cell survival.
• Regulates cardiomyocyte cohesion; cholinergic signaling impairs this process, linking to heart disease.
• Serves as a potential therapeutic target for disrupting oncogenic protein-protein interactions.
• Plays a role in desmosomal diseases such as arrhythmogenic right ventricular cardiomyopathy.
• Influences cell signaling pathways beyond adhesion, including transcriptional regulation.
• Provides a mechanism for cancer cells to evade therapies targeting beta-catenin.
• Is essential for normal development and tissue homeostasis.
Molecular Mechanism of gamma-catenin binding
Structural Basis of Gamma-Catenin Binding
In simple terms: Gamma-catenin has specific regions that allow it to stick to other proteins.
Gamma-catenin (plakoglobin) contains multiple armadillo repeats that mediate protein-protein interactions. These repeats form a superhelix that binds to the cytoplasmic domains of desmosomal and adherens junction cadherins, such as desmoglein and E-cadherin. The binding is essential for linking these cadherins to the intermediate filament and actin cytoskeletons, respectively.
Interaction with Desmosomal Cadherins
In simple terms: Gamma-catenin connects desmosomal cadherins to the cell's internal skeleton.
In desmosomes, gamma-catenin binds to the cytoplasmic tails of desmogleins and desmocollins, forming the outer dense plaque. This interaction is required for desmosome assembly and maintenance of tissue integrity. Mutations in desmosomal cadherins or gamma-catenin that disrupt this binding lead to skin and heart disorders.
Role in Adherens Junctions
In simple terms: Gamma-catenin also works in another type of cell junction called adherens junctions.
In adherens junctions, gamma-catenin can bind to E-cadherin and alpha-catenin, although beta-catenin is the primary partner. When beta-catenin is depleted, gamma-catenin can substitute to maintain adherens junction function and promote cancer cell survival. This plasticity highlights the importance of gamma-catenin binding in cellular adaptation.
Transcriptional Regulation via CBP
In simple terms: Gamma-catenin can also enter the nucleus and influence gene expression.
Gamma-catenin binds to CBP (CREB-binding protein) to form a transcriptional complex that maintains survivin expression in beta-catenin-deficient cancer cells. This complex supports cell survival and proliferation, demonstrating a nuclear function for gamma-catenin binding beyond cell adhesion.
Regulation by Signaling Pathways
In simple terms: Signals from outside the cell can change how gamma-catenin binds to its partners.
Cholinergic signaling impairs cardiomyocyte cohesion by affecting gamma-catenin binding, possibly through phosphorylation or altered expression. Additionally, FOXM1-JUP signaling deregulates transcription in pancreatic cancer, indicating that gamma-catenin binding is modulated by oncogenic pathways.
Key Genes Involved in GO:0045295 gamma-catenin binding
The following genes and proteins are key players in gamma-catenin binding and its associated functions.
| Gene | Major Role | Research Relevance |
|---|---|---|
| JUP | Encodes gamma-catenin (plakoglobin), the central protein in this GO term. | Mutations cause arrhythmogenic right ventricular cardiomyopathy; target in cancer and cardiac research. |
| DSC2 | Desmocollin 2, a desmosomal cadherin that binds gamma-catenin. | Mutations linked to arrhythmogenic cardiomyopathy; studied for junction assembly. |
| DSG2 | Desmoglein 2, another desmosomal cadherin binding gamma-catenin. | Involved in cell adhesion; target for understanding desmosome dynamics. |
| CDH1 | E-cadherin, binds gamma-catenin in adherens junctions. | Loss promotes cancer invasion; studied in epithelial cancers. |
| CTNNB1 | Beta-catenin, competes with gamma-catenin for binding sites. | Its knockdown leads to gamma-catenin compensation in cancer. |
| CTNNA1 | Alpha-catenin, links cadherins to actin cytoskeleton. | Interacts with gamma-catenin in adherens junctions. |
| CREBBP | CBP, binds gamma-catenin to regulate transcription. | Forms complex with gamma-catenin to maintain survivin expression. |
| BIRC5 | Survivin, a target gene of gamma-catenin/CBP complex. | Promotes cell survival; overexpressed in cancers. |
| FOXM1 | Transcription factor that regulates JUP expression. | Drives pancreatic tumorigenesis via JUP signaling. |
| BCL9 | B-cell lymphoma 9, interacts with beta-catenin. | Target for disrupting beta-catenin/BCL9 interaction; may affect gamma-catenin. |
| CHRM2 | Muscarinic acetylcholine receptor, mediates cholinergic signaling. | Impairs cardiomyocyte cohesion via gamma-catenin. |
| PKP2 | Plakophilin 2, another desmosomal protein. | Mutations cause cardiomyopathy; interacts with gamma-catenin. |
| DSP | Desmoplakin, links desmosomes to intermediate filaments. | Binds gamma-catenin; mutations in cardiomyopathy. |
| GJA1 | Connexin 43, gap junction protein. | Cross-talk with desmosomes; affected by gamma-catenin loss. |
| VCL | Vinculin, cytoskeletal protein. | Interacts with gamma-catenin in adherens junctions. |
| ACTN1 | Alpha-actinin, actin crosslinker. | May associate with gamma-catenin complexes. |
| KRT5 | Keratin 5, intermediate filament protein. | Links to desmosomes via gamma-catenin. |
| KRT14 | Keratin 14, intermediate filament protein. | Partners with gamma-catenin in desmosomes. |
How Is gamma-catenin binding Regulated?
Gamma-catenin binding is regulated at multiple levels. Transcriptional regulation of JUP by FOXM1 affects gamma-catenin levels and subsequent binding in pancreatic cancer. Post-translational modifications, such as phosphorylation, can modulate gamma-catenin's affinity for cadherins and other partners. Cholinergic signaling impairs cardiomyocyte cohesion, likely by altering gamma-catenin phosphorylation or localization. Additionally, the availability of binding partners like CBP and cadherins influences complex formation. Competitive binding with beta-catenin also regulates gamma-catenin's role in adherens junctions.
gamma-catenin binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| JUP | Arrhythmogenic right ventricular cardiomyopathy; cancer | Knockout mice, patient-derived iPSC cardiomyocytes |
| CTNNB1 | Hepatocellular carcinoma; beta-catenin depletion | Liver cancer cell lines with beta-catenin knockdown |
| FOXM1 | Pancreatic cancer; therapeutic resistance | Pancreatic cancer organoids, xenografts |
| CREBBP | Cancer; survivin transcription | Cancer cell lines with CBP inhibition |
| DSC2 | Arrhythmogenic cardiomyopathy | Knockout zebrafish, mouse models |
Gamma-Catenin Binding in Hepatocellular Carcinoma
In hepatocellular carcinoma, gamma-catenin can compensate for beta-catenin loss and promote tumorigenesis. Knockdown of beta-catenin leads to increased gamma-catenin at adherens junctions, where it maintains cell adhesion and survival. The gamma-catenin/CBP complex sustains survivin transcription, contributing to chemoresistance. These findings suggest that targeting gamma-catenin binding could be therapeutic in liver cancer.
Gamma-Catenin Binding in Pancreatic Cancer
FOXM1-JUP signaling drives pancreatic tumorigenesis and therapeutic resistance. JUP (gamma-catenin) is transcriptionally upregulated by FOXM1, leading to enhanced gamma-catenin binding and oncogenic signaling. This axis represents a potential target for pancreatic cancer therapy.
Gamma-Catenin Binding in Cardiac Disease
Cholinergic signaling impairs cardiomyocyte cohesion by disrupting gamma-catenin binding, contributing to arrhythmogenic cardiomyopathy. Mutations in JUP cause arrhythmogenic right ventricular cardiomyopathy, highlighting the importance of gamma-catenin binding in heart tissue. Understanding these mechanisms may lead to new treatments for cardiac arrhythmias.
From gamma-catenin binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| What is the role of gamma-catenin in desmosome assembly? | JUP knockout keratinocytes or cardiomyocytes |
| How does gamma-catenin compensate for beta-catenin loss in cancer? | CTNNB1 knockout hepatocellular carcinoma cells |
| Does gamma-catenin binding to CBP regulate survivin? | JUP point mutants unable to bind CBP |
| How does FOXM1 regulate JUP expression? | FOXM1 knockout pancreatic cancer cells |
| What is the effect of cholinergic signaling on gamma-catenin binding? | Cardiomyocytes treated with cholinergic agonists |
| Can disrupting beta-catenin/BCL9 affect gamma-catenin binding? | Peptidomimetic foldamer treatment in cancer cells |
How to Study the gamma-catenin binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Co-IP | Protein-protein interactions | Detect gamma-catenin binding to cadherins |
| FRET | Dynamic interactions in live cells | Measure gamma-catenin binding kinetics |
| RNA-seq | Transcriptional changes | Identify genes regulated by gamma-catenin/CBP |
| Proteomics | Protein abundance and modifications | Discover novel gamma-catenin partners |
| CRISPR screen | Gene function on a genome-wide scale | Find modifiers of gamma-catenin binding |
| Immunofluorescence | Protein localization | Visualize gamma-catenin at junctions |
| Western blot | Protein expression and phosphorylation | Assess gamma-catenin levels |
| Luciferase reporter | Transcriptional activity | Measure CBP-mediated transcription |
Co-Immunoprecipitation (Co-IP) and Pull-Down Assays
Co-IP is used to detect physical interactions between gamma-catenin and its binding partners, such as cadherins and CBP. Pull-down assays with recombinant proteins can map binding domains. These methods are fundamental for studying gamma-catenin binding.
Fluorescence Microscopy and FRET
Immunofluorescence microscopy localizes gamma-catenin at desmosomes and adherens junctions. FRET (Förster resonance energy transfer) can measure dynamic interactions in live cells. These techniques reveal spatial and temporal aspects of gamma-catenin binding.
Transcriptomics and Proteomics
RNA-seq identifies transcriptional changes upon gamma-catenin modulation, such as survivin upregulation. Proteomics can uncover novel binding partners and post-translational modifications. These high-throughput methods provide systems-level insights.
CRISPR-Based Genetic Screens
CRISPR knockout screens can identify genes that modulate gamma-catenin binding or its downstream effects. Such screens are powerful for discovering synthetic lethal interactions.
How CRISPR Can Be Used to Study GO:0045295 gamma-catenin binding
Knockout
CRISPR knockout of JUP eliminates gamma-catenin expression, disrupting desmosome and adherens junction formation. This model is used to study the consequences of loss of gamma-catenin binding in cancer and cardiac cells. Knockout of CTNNB1 can induce compensatory gamma-catenin binding.
Point Mutation
Point mutations in JUP can abrogate specific binding interactions, such as with CBP or cadherins. These models help dissect the distinct roles of gamma-catenin binding partners. For example, mutations in the armadillo repeats can disrupt cadherin binding.
Knock-in
Knock-in of tagged gamma-catenin (e.g., GFP or HA) allows for visualization and purification of binding complexes. This approach enables proteomic identification of endogenous binding partners. Knock-in of disease-associated mutations can model cardiomyopathy.
Overexpression
Overexpression of gamma-catenin can drive oncogenic signaling and compensate for beta-catenin loss. It is used to study gain-of-function effects in cancer models. Overexpression in cardiomyocytes can disrupt cohesion.
How EDITGENE Supports gamma-catenin binding Research
Researchers studying gamma-catenin binding-related genes often need to determine whether a candidate gene is causally involved in junction assembly, transcriptional regulation, or disease progression. EDITGENE provides comprehensive CRISPR services to accelerate this research.
Contact EDITGENE today to design your custom CRISPR model for gamma-catenin binding research.
Frequently Asked Questions About gamma-catenin binding
What is gamma-catenin binding?
Gamma-catenin binding (GO:0045295) is the molecular function of binding to the catenin complex gamma subunit, also known as plakoglobin, which is involved in cell-cell adhesion.
What genes are involved in gamma-catenin binding?
Key genes include JUP (encoding gamma-catenin), DSC2, DSG2, CDH1, CTNNB1, CREBBP, and FOXM1, among others.
What diseases are associated with gamma-catenin binding?
Diseases include hepatocellular carcinoma, pancreatic cancer, and arrhythmogenic right ventricular cardiomyopathy.
How is gamma-catenin binding regulated?
It is regulated by transcriptional control (e.g., FOXM1), post-translational modifications, and signaling pathways such as cholinergic signaling.
What is the difference between gamma-catenin and beta-catenin?
Gamma-catenin (plakoglobin) is found in both desmosomes and adherens junctions, while beta-catenin is primarily in adherens junctions and Wnt signaling; they can compensate for each other.
What methods are used to study gamma-catenin binding?
Common methods include co-immunoprecipitation, FRET, immunofluorescence, RNA-seq, proteomics, and CRISPR screens.
Can gamma-catenin binding be targeted therapeutically?
Yes, disrupting gamma-catenin interactions, such as with CBP, is a potential therapeutic strategy in cancer.
What is the role of gamma-catenin in cancer?
Gamma-catenin can promote tumorigenesis by compensating for beta-catenin loss and sustaining survivin expression.
How does cholinergic signaling affect gamma-catenin binding?
Cholinergic signaling impairs cardiomyocyte cohesion by disrupting gamma-catenin binding, contributing to heart disease.
What CRISPR models are available for gamma-catenin binding research?
EDITGENE offers knockout, point mutation, knock-in, and overexpression models for genes like JUP and CTNNB1.
Conclusion
Gamma-catenin binding (GO:0045295) is a fundamental molecular function that underpins cell-cell adhesion and signaling. Its dysregulation is implicated in cancer and cardiac diseases, making it a compelling target for research and therapy. Understanding the mechanisms and regulation of gamma-catenin binding will continue to reveal new insights into human health and disease.
References
- 2. Yang K et al.. 2025. Transcriptional deregulation by FOXM1-JUP signaling confers dual oncogenic drivers for pancreatic tumorigenesis and therapeutic resistance.. Cell Commun Signal 23(1):513 PMID: 41310714
- 4. Delva E et al.. 2009. The desmosome.. Cold Spring Harb Perspect Biol 1(2):a002543 PMID: 20066089
- 5. Wickline ED et al.. 2013. γ-Catenin at adherens junctions: mechanism and biologic implications in hepatocellular cancer after β-catenin knockdown.. Neoplasia 15(4):421-34 PMID: 23555187
- 6. Kim YM et al.. 2011. The gamma catenin/CBP complex maintains survivin transcription in β-catenin deficient/depleted cancer cells.. Curr Cancer Drug Targets 11(2):213-25 PMID: 21158719
- 7. Sang P et al.. 2025. Disruption of β-Catenin/B-Cell Lymphoma 9 Protein-Protein Interaction Using Heterogeneous Peptidomimetic Foldamers.. J Am Chem Soc 147(45):41819-41829 PMID: 41178037
- 8. Yeruva S et al.. 2022. Cholinergic signaling impairs cardiomyocyte cohesion.. Acta Physiol (Oxf) 236(3):e13881 PMID: 36039679
